Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer

Cancer

Volumn 117, Issue 2, 2011, Pages 318-326

  Kao, Johnny ^a   Genden, Eric M ^a   Gupta, Vishal ^a   Policarpio, Edelweiss L ^a   Burri, Ryan J ^a   Rivera, Michael ^a   Gurudutt, Vivek ^a   Som, Peter M ^a   Teng, Marita ^a   Packer, Stuart H ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

cetuximab; chemoradiation; epidermal growth factor receptor; head and neck cancer; intensity modulated radiation therapy

Indexed keywords

CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; HYDROXYUREA;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; DERMATITIS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HIGH RISK PATIENT; HUMAN; HUMAN CELL; INFECTION; INTENSITY MODULATED RADIATION THERAPY; LEUKOPENIA; LUNG TOXICITY; MALE; MORNING DOSAGE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION DOSE FRACTIONATION; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TASTE; THROMBOCYTOPENIA; THRUSH; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; HYDROXYUREA; MALE; MIDDLE AGED; QUALITY OF LIFE; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 78650968294     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25374     Document Type: Article

References (28)

1. Lavaf A, Genden EM, Cesaretti JA, Packer S, Kao J,. Adjuvant radiotherapy improves overall survival for patients with lymph node-positive head and neck squamous cell carcinoma. Cancer. 2008; 112: 535-543.
2. Forastiere A, Koch W, Trotti A, Sidransky D,. Head and neck cancer. N Engl J Med. 2001; 345: 1890-1900.
3. Haddad RI, Shin DM,. Recent advances in head and neck cancer. N Engl J Med. 2008; 359: 1143-1154.
4. Salama JK, Seiwert TY, Vokes EE,. Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol. 2007; 25: 4118-4126.
5. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and 2 schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003; 21: 92-98.
6. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998; 338: 1798-1804.
7. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004; 350: 1937-1944.
8. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; 349: 2091-2098.
9. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004; 350: 1945-1952. (Pubitemid 38580197)
10. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354: 567-578.
11. Adelstein DJ, Saxton JP, Rybicki LA, et al. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol. 2006; 24: 1064-1071.
12. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006; 368: 843-854. (Pubitemid 44292807)
13. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007; 357: 1705-1715.
14. Vokes EE, Stenson K, Rosen FR, et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003; 21: 320-326.
15. Haraf DJ, Rosen FR, Stenson K, et al. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res. 2003; 9 (16 pt 1): 5936-5943.
16. Salama JK, Stenson KM, Kistner EO, et al. Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating 3 radiotherapy dose levels. Ann Oncol. 2008; 19: 1787-1794.
17. Ahmed SM, Cohen EE, Haraf DJ, al. E. Updated results of a phase II trial integrating gefitinib (G) into concurrent chemoradiation (CRT) followed by G adjuvant therapy for locally advanced head and neck cancer (HNC) [abstract]. J Clin Oncol. 2007; 25 (18S). Abstract 6028a.
18. Huang SM, Bock JM, Harari PM,. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999; 59: 1935-1940.
19. Burri RJ, Rangaswamy B, Kostakoglu L, et al. Correlation of positron emission tomography standard uptake value and pathologic specimen size in cancer of the head and neck. Int J Radiat Oncol Biol Phys. 2008; 71: 682-688.
20. Chen C, Kane M, Song J, et al. Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. J Clin Oncol. 2007; 25: 4880-4886.
21. Harrington KJ, El-Hariry IA, Holford CS, et al. Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2009; 27: 1100-1107.
22. Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol. 2006; 24: 1072-1078.
23. Kao J, Vu HL, Genden EM, et al. The diagnostic and prognostic utility of positron emission tomography/computed tomography-based follow-up after radiotherapy for head and neck cancer. Cancer. 2009; 115: 4586-4594.
24. Herbst RS, Kim ES, Harari PM,. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin Biol Ther. 2001; 1: 719-732.
25. Adelstein DJ, Moon J, Hanna E, et al. Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/ concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: a Southwest Oncology Group phase II trial (S0216). Head Neck. 2010; 32: 221-228.
26. Vu HL, Sikora AG, Fu S, Kao J,. HPV-induced oropharyngeal cancer, immune response and response to therapy. Cancer Lett. 2010; 288: 149-155.
27. Egloff AM, Grandis JR,. Improving response rates to EGFR-targeted therapies for head and neck squamous cell carcinoma: candidate predictive biomarkers and combination treatment with Src inhibitors. J Oncol. 2009; 2009: 896407-896407.
28. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008; 100: 261-269.